PMC6302808_01
Patient's clinical course including treatment history and relevant imaging studies and tumor biopsy specimen studies.. Notes: (A) The patient was diagnosed with lung adenocarcinoma harboring EGFR 19 Del in December 2012 and was administrated with gefitinib treatment. (B) NGS of tumor biopsy in April 2015 showed EGFR T790M in addition to EGFR 19 Del and the patient was administrated with osimertinib. (C) NGS of blood sample in June 2016 showed an acquired G724S mutation, MAP2K1 and TP53 mutation along with the EGFR 19 Del and T790M mutation. The patient was treated with osimertinib, gefitinib, cabozantinib, and pembrolizumab. (D and E) NGS of blood sample in August and September 2016 showed additional MET amplification.. Abbreviations: PMCT, percutaneous microwave coagulation therapy; NGS, next-generation sequencing.
ott-12-051Fig1.jpg
PMC6302808_01_ott-12-051Fig1.jpg
f1-ott-12-051
All the processes of diagnosis and treatment are shown below (Figure 1 and Table 1).